<DOC>
	<DOCNO>NCT00088647</DOCNO>
	<brief_summary>The primary objective clinical research study evaluate safety , tolerability , maximum tolerate dose ( MTD ) intravenous ( IV ) MST-997 formulate Intralipid 20 % administered weekly schedule subject advance malignant solid tumor .</brief_summary>
	<brief_title>Study Evaluating MST-997 Advanced Malignant Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<criteria>Documented histological cytological diagnosis confirm presence malignant solid tumor Tumor progression conventional therapy cancer malignant solid tumor conventional therapy exist Subjects enrol MTD confirmation cohort document histologic and/or cytologic diagnosis metastatic breast cancer nonsmall cell lung cancer ( NSCLC ) receive 2 prior chemotherapy regimens metastatic disease ( adjuvant neoadjuvant chemotherapy include maximum 2 prior regimen describe ) Subjects symptomatic clinically active central nervous system ( CNS ) metastases . Subjects prior treatment radiotherapy surgical resection CNS metastases permit CNS metastasis remain stable require treatment least 3 month prior first dose test article History primary malignancy le 5 year documentation diseasefree state ( Subjects history basal cell squamous cell carcinoma skin cervical carcinoma situ , successfully treat , exclude ) Recent major surgery ( within 14 day first dose ) chemotherapy within 28 day first dose MST997 ( 42 day previous chemotherapy include nitrosoureas mitomycin C )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>advanced malignant solid tumor</keyword>
	<keyword>breast cancer</keyword>
</DOC>